Equity is given less attention than efficiency in HEE guidelines. This indicates that HTA agencies while subscribing to an extra-welfarist approach have a narrow evaluative space – focusing on maximising health and not considering the opportunity cost of the equity constraint.
The Government has just announced it’s ending what it calls a nearly 30-year ban on gene technology outside the lab. What does that mean? Science reporter Jamie Morton explains.
This year, according to data from the Institute of Environmental Science and Research, the Auckland metropolitan area has had the most hospitalisations from influenza-like illness since 2015.
The very idea of Pharmac presents a conundrum for the minister in charge, Act leader David Seymour.
New Zealand and the United States are the only high-income countries to allow unrestricted direct-to-consumer advertising of branded medicines, including the name of the drug and the condition for which it is prescribed.
Health New Zealand Te Whatu Ora has backed down on a plan to delay free access to a life-extending cancer drug after a backlash by patients and advocates.
Health New Zealand is moving forward implementation planning to ensure a small group of cancer patients can take advantage of free early access to the drug Keytruda shortly ahead of Pharmac starting to fund the medication.
Patient advocates are accusing Health New Zealand of "cruelty" towards a small group of cancer patients, who are being forced to wait two more months for a newly-funded drug.
Experts are calling for the flu vaccine for under 12-year-olds to be fully funded - again.
Associate health minister David Seymour’s directive to Pharmac may streamline decisionmaking but it downplays the true role of the Treaty of Waitangi, writes Dominic O’Sullivan
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI